Altered fibrin clot properties in patients on long-term haemodialysis: Relation to cardiovascular mortality

Nephrology Dialysis Transplantation

Volumn 23, Issue 6, 2008, Pages 2010-2015

  Undas, Anetta ^a   Kolarz, Marek ^b   Kopeć, Grzegorz ^a   Tracz, Wiesława ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Haemodialysis Unit Miechow   (Poland)

Author keywords

Fibrin clot; Fibrinolysis; Haemodialysis; Mortality

Indexed keywords

ALTEPLASE; FIBRIN; FIBRINOGEN; ISOPROSTANE DERIVATIVE; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; BLOOD CLOT; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; LONG TERM CARE; MALE; MASS; MORTALITY; OXIDATIVE STRESS; PERMEABILITY; POROSITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THICKNESS; TIME; TREATMENT DURATION; TURBIDITY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY THROMBOSIS; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HUMANS; KIDNEY FAILURE, CHRONIC; LONG-TERM CARE; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PERMEABILITY; PROBABILITY; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 44449178835     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm884     Document Type: Article

References (34)

1. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol 2004; 44: 1343-1353
2. McCullogh PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 2004; 13: 591-600
3. Nurmohamed SA, Nube MJ. Reverse epidemiology: paradoxical observations in haemodialysis patients. Net J Med 2005; 63: 376-381
4. Cheung AK, Sarnak MJ, Yan G et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 2004; 65: 2380-2389
5. Yao Q, Pecoits-Filho R, Lindholm B et al. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol 2004; 38: 405-416
6. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-1904
7. Scott EM, Ariëns RAS, Grant PJ. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566
8. Undas A, Zeglin M. Fibrin clot structure and cardiovascular disease. Vasc Dis Prevention 2006; 3: 99-106
9. Undas A, Brozek J, Jankowski M et al. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006; 26: 1397-1404
10. Undas A, Stepien E, Tracz W et al. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 2006; 4: 973-975
11. Undas A, Celinska-Lowenhoff M, Lowenhoff T et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036
12. Undas A, Szuldrzynski K, Stepien E et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: Effects of inflammation and oxidative stress. Atherosclerosis 2007 (in press).
13. Collet JP, Allali Y, Lesty C et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573
14. Mills JD, Ariëns RA, Mansfield MWet al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942
15. Dunn EJ, Ariëns RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologica 2005: 48; 1198-1206
16. Collet J-P, Mishal Z, Lesty C et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost 1999; 82: 1482-1489
17. Holloway DS, Vagher JP, Caprini JA et al. Thromboelastography of blood from subjects with chronic renal failure. Thromb Res 1987; 45: 817-825
18. Sjoland JA, Sidelmann JJ, Brabrand M et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98: 339-345
19. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 1502-1513
20. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52
21. Daugirdas JT. Second generation logarithmic estimates of single-pool variable-volume kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
22. Blombäck B, Carlsson K, Hessel B et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110
23. Williams S, Fatah K, Ivert T et al. The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis 1995; 6: 718-725
24. Carr ME , Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995; 6: 567-573
25. Collet JP, Park D, Lesty C et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed. Dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361
26. Zoccali C, Mallamaci F, Tripepi G et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003; 254: 132-139
27. Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992; 63: 111-128
28. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients long-term hemodialysis. Kidney Int 2001; 59: 1960-1966
29. Locatelli F, Canaud B, Eckatelli L et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2006; 18: 1272-1280
30. Bayes B, Pastor MC, Bonal J et al. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis - role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial Transplant 2006; 21: 984-990
31. Shacter E, Williams JA, Lim M et al. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 1994; 17: 429-437
32. Feng YH, Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Cardiovasc Res 1995; 30: 255-261
33. Frischmann ME, Kronenberg F, Trenkwalder E et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007; 71: 1036-1043
34. Tsurupa G, Ho-Tin-Noe B, Anles-Cano E et al. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) αC-domains. J Biol Chem 2003; 278: 37154-37159